Sino Biopharmaceutical(CH:SMZ1)
CHF 0.58+0.01 (+0.87%)
CH:SMZ1
Sino Biopharmaceutical ownership
CHF 0.58
At close:+0.01 (+0.87%)
Sino Biopharmaceutical (SMZ1) Ownership - Who Owns Sino Biopharmaceutical?
0 Followers
Sino Biopharmaceutical (SMZ1) Ownership Overview
- 15.79% Insiders
- 2.71% Mutual Funds
- <0.01% Other Institutional Investors
- 6.30% ETFs
- 75.20% Public Companies and Individual Investors
The ownership structure of Sino Biopharmaceutical (CH:SMZ1) stock is a mix of institutional, retail, and individual investors. Approximately 9.01% of the company’s stock is owned by Institutional Investors, 15.79% is owned by Insiders, and 75.20% is owned by Public Companies and Individual Investors.
The ownership structure of Sino Biopharmaceutical (CH:SMZ1) stock is a mix of institutional, retail, and individual investors. Approximately 9.01% of the company’s stock is owned by Institutional Investors, 15.79% is owned by Insiders, and 75.20% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Apr 29, 2026 | Cheung Ling Cheng | HK$5,441,000 | |
| Apr 28, 2026 | Cheung Ling Cheng | HK$5,470,500 | |
| Apr 28, 2026 | Ping Tse | HK$11,047,000 | |
| Apr 27, 2026 | Cheung Ling Cheng | HK$16,284,600 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Ping Tse | 1,694,270,241 | Insider | 9.07% | 1,202,931,871 |
| Cheung Ling Cheng | 887,034,750 | Insider | 4.75% | 629,794,673 |
| Ishares | 404,543,630 | Institution | 2.17% | 287,225,977 |
| Hsin Tse | 360,557,270 | Insider | 1.93% | 255,995,662 |
| Vanguard | 346,993,432 | Institution | 1.86% | 246,365,337 |
| Vanguard International Equity Index Funds | 168,024,412 | Institution | 0.90% | 119,297,333 |
| Vanguard Star Funds | 140,861,818 | Institution | 0.75% | 100,011,891 |
| Amundi | 98,610,613 | Institution | 0.53% | 70,013,535 |
| Dfa Investment Dimensions Group Inc | 85,063,990 | Institution | 0.46% | 60,395,433 |
| Ubs | 69,329,250 | Institution | 0.37% | 49,223,768 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard International Equity Index Funds | 168,024,412 | Institution | 0.90% | 119,297,333 |
| Vanguard Star Funds | 140,861,818 | Institution | 0.75% | 100,011,891 |
| Dfa Investment Dimensions Group Inc | 85,063,990 | Institution | 0.46% | 60,395,433 |
| Fidelity Salem Street Trust | 47,022,352 | Institution | 0.25% | 33,385,870 |
| Tiaa-cref Funds | 16,571,662 | Institution | 0.09% | 11,765,880 |
| Hartford Mutual Funds, Inc | 7,310,470 | Institution | 0.04% | 5,190,434 |
| Mercer Funds | 4,809,000 | Institution | 0.03% | 3,414,390 |
| Northern Funds | 4,433,500 | Institution | 0.02% | 3,147,785 |
| State Street Institutional Investment Trust | 3,613,000 | Institution | 0.02% | 2,565,230 |
| Fidelity Rutland Square Trust Ii | 3,125,000 | Institution | 0.02% | 2,218,750 |
FAQ
Who Owns Sino Biopharmaceutical (CH:SMZ1)?
According to the latest TipRanks data, approximately 9.01% of the company's stock is held by institutional investors, 15.79% is held by insiders, and 75.20% is held by public companies and individual investors.
What percentage of Sino Biopharmaceutical (CH:SMZ1) stock is held by institutional investors?
According to the latest TipRanks data, approximately 9.01% of Sino Biopharmaceutical (CH:SMZ1) stock is held by institutional investors: 2.71% by mutual funds, 6.30% by ETFs and <0.01% by other institutional investors.
What percentage of Sino Biopharmaceutical (CH:SMZ1) stock is held by retail investors?
According to the latest TipRanks data, approximately 75.20% of Sino Biopharmaceutical (CH:SMZ1) stock is held by public companies and individual investors.
Who owns the most shares of Sino Biopharmaceutical (CH:SMZ1)?
Ping Tse owns the most shares of Sino Biopharmaceutical (CH:SMZ1).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
